Home › NDC Lookup › RxCUI directory › RxCUI 833234

Mesalamine 800 MG Delayed Release Oral Tablet — RxCUI 833234

RxNorm drug concept · Semantic clinical drug
RxCUI 833234 Semantic clinical drug · SCD ● Current RxNorm concept 6 FDA products 8 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI833234
Official nameMesalamine 800 MG Delayed Release Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asmesalazine 800 MG Delayed Release Oral Tablet
FDA products mapped6
Package NDCs mapped8
Reported Medicaid activity (SDUD)8,454 prescriptions · 27 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Mesalamine Rectal: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Mesalamine rectal works by calming the inflammation directly in the lining of your rectum and lower colon — the area affected by your condition. It blocks some of the chemical sign...
  • What exactly is this medication doing for my colitis?
  • Treatment is typically continued for 3 to 6 weeks depending on your symptoms and what your doctor sees during examination. It's important to keep using it for the full course your...
  • How long do I need to use it before it starts working?
📖 Read our full Mesalamine Rectal guide →

🕸️ Concept Web — How Mesalamine 800 MG Delayed Release Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Mesalamine 800 MG Delayed Release Oral Tablet RxCUI 833234

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Mesalamine 52582
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Mesalamine Delayed Release Oral Tablet 372784
    • Mesalamine Oral Product 1165714
    • Mesalamine Pill 1165715
    • Delayed Release Oral Tablet 10312
    • Oral Product 1151131
    • Pill 1151133
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Mesalamine 800 MG 833233

Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Mesalamine 800 MG SCDC · 833233
  • Mesalamine Delayed Release Oral Tablet SCDF · 372784
  • Mesalamine Oral Product SCDG · 1165714
  • Mesalamine Pill SCDG · 1165715

📦 FDA Products & Package NDCs

6 products · 8 package NDCs
8 package NDCs map to RxCUI 833234 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00480-7750-80 180 TABLET, DELAYED RELEASE in 1 BOTTLE (0480-7750-80) Mesalamine Teva Pharmaceuticals, Inc. 2024-08-22
42291-0489-18 180 TABLET, DELAYED RELEASE in 1 BOTTLE (42291-489-18) Mesalamine AvKARE 2024-09-25
60687-0408-25 30 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-408-25) / 1 TABL... Mesalamine American Health Packaging 2019-04-17
65162-0360-18 180 TABLET, DELAYED RELEASE in 1 BOTTLE (65162-360-18) Mesalamine Amneal Pharmaceuticals LLC 2025-02-19
68382-0435-28 180 TABLET, DELAYED RELEASE in 1 BOTTLE (68382-435-28) mesalamine Zydus Pharmaceuticals USA Inc. 2018-08-02
68382-0435-77 10 BLISTER PACK in 1 CARTON (68382-435-77) / 10 TABLET, DEL... mesalamine Zydus Pharmaceuticals USA Inc. 2018-08-02
70771-1110-04 10 BLISTER PACK in 1 CARTON (70771-1110-4) / 10 TABLET, DEL... mesalamine Zydus Lifesciences Limited 2018-08-02
70771-1110-08 180 TABLET, DELAYED RELEASE in 1 BOTTLE (70771-1110-8) mesalamine Zydus Lifesciences Limited 2018-08-02
Observed labelers: Zydus Lifesciences Limited (2) · Zydus Pharmaceuticals USA Inc. (2) · American Health Packaging (1) · Amneal Pharmaceuticals LLC (1) · AvKARE (1) · Teva Pharmaceuticals, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$4.3205
Range $4.3205–$4.3205 · middle 50% $4.3205–$4.3205 · 4 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.